All In MedTech

Device Trial Radar · NCT03993210

The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids

Last checked: Nov 19, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

1

Actual

Start

Sep 18, 2019

Primary completion

Sep 19, 2019

Study completion Sep 19, 2019

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 20, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting and Q-space Trajectory Imaging in gynecological abnormalities. The purpose of this research study is to evaluate if these new MRI methods can give additional information in characterizing gynecological tumors compared with conventional MRI.

Conditions

  • Gynecologic Tumor

Interventions

  • Magnetic Resonance Fingerprinting (MRF)Device

    In MRF, multiple tissue properties are acquired simultaneously.

  • Q-space Trajectory Imaging (QTI)Device

    By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.

  • Magnetic Resonance Imaging Machine (MRI)Device

    MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Feasible ImagingTime frame: Day 1

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.